Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tdap-IPV vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tdap-IPV is a quadrivalent combination booster vaccine designed to provide active immunity against tetanus, diphtheria, pertussis (whooping cough), and poliomyelitis. It typically contains tetanus toxoid, diphtheria toxoid, acellular pertussis antigens (such as pertussis toxoid, filamentous hemagglutinin, and pertactin), and inactivated poliovirus (IPV) types 1, 2, and 3. In the context of the Phase 4 KIM (Tdap-IPV Challenge Study) led by Dimitri Diavatopoulos at Radboud University Medical Center, the vaccine is being investigated for its ability to reduce nasal colonization of *Bordetella pertussis* in healthy adults using a controlled human infection model. This research aims to determine if booster vaccination with acellular pertussis vaccines can impact bacterial carriage and transmission, potentially contributing to herd immunity beyond the prevention of clinical disease.
- Brand names
- Boostrix-IPVRepevaxAdacel-Polio
- Other names
- Tdap-IPVTetanus-Diphtheria-Acellular Pertussis-Inactivated Poliovirus VaccineTetanus, diphtheria, acellular pertussis, and inactivated poliovirus vaccine
02
Targets
FHA (Filamentous hemagglutinin)Poliovirus capsid proteinsTLR8 (Toll-like receptor 8)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Tdap-IPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tdap-IPV vaccine.